The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability: The Report of Final Results
Abstract
STUDY OBJECTIVE: To determine the effectiveness, toxicity, and acceptability of a 6-month antituberculous regimen compared with a 9-month regimen. DESIGN: A nonblinded, unbalanced, randomized, multicenter clinical trial. SETTING: Twenty-two tuberculosis clinics in public health departments and hospitals in the United States. PATIENTS: Patients were eligible if Mycobacterium tuberculosis, isolated from sputum cultures, was susceptible to study drugs. Of 1451 patients enrolled, 75% (617 of 823) assigned to the 6-month regimen and 71% (445 of 628) assigned to the 9-month regimen were eligible. INTERVENTIONS: Patients took self-administered isoniazid and rifampin daily for 24 weeks (6-month regimen) or 36 weeks (9-month regimen). In addition, patients assigned to the 6-month regimen took self-administered pyrazinamide daily during the first 8 weeks. RESULTS: Patients on the 6-month regimen converted more rapidly than patients on the 9-month regimen (94.6% compared with 89.9% after 16 weeks of therapy, with a difference of 4.7% [95% CI, 0.7% to 8.7%]); had similar rates of adverse drug reactions (7.7% compared with 6.4%, with a difference of 1.3% [95% CI, 0.0% to 4.6%]); had lower noncompliance rates (16.8% compared with 29.2%, with a difference of 12.4% [95% CI, 6.8% to 18.0%]); and had similar relapse rates 96 weeks after completing therapy (3.5% compared with 2.8%, with a difference of 0.7% [95% CI, 0.0% to 3.9%]). A significantly greater proportion of patients assigned to the 6-month regimen successfully completed therapy (61.4% compared with 50.6%; chi 2 = 11.976). CONCLUSIONS: Our results suggest that this 6-month regimen is similar in effectiveness, toxicity, and acceptability to the 9-month regimen for treating pulmonary tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The action of antituberculosis drugs in short-course chemotherapy
Mitchison, D. A. (1985) · Tubercle · doi:10.1016/0041-3879(85)90040-6 · Cited by 518
The consent form as a possible cause of side effects
Myers, M. G., Cairns, J. A., & Singer, J. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.142 · Cited by 219
Hong Kong Chest Service/British Medical Research Council (1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.6.1339 · Cited by 126
Singapore, T. S. B. M. (1981) · Tubercle · doi:10.1016/0041-3879(81)90016-7 · Cited by 92
Geiter, L. J., O'Brien, R. J., Combs, D. L., & Snider, D. E. (1987) · Tubercle · doi:10.1016/s0041-3879(87)80021-1 · Cited by 29
Self-citation
Cited by
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Tuberculosis: Commentary on a Reemergent Killer
Bloom, B. R., & Murray, C. J. L. (1992) · Science · doi:10.1126/science.257.5073.1055 · Cited by 1,373
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Metadata
- Authors
- Combs, D. L., O'Brien, R. J., & Geiter, L. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1990-03-15
- Volume
- 112
- Issue
- 6
- Pages
- 397-406
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2008756350
- Cited by
- 315
- References
- 5
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability: The Report of Final Results. https://app.cochat.ai/papers/10.7326/0003-4819-76-3-112-6-397
- The paper
- Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990). USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability: The Report of Final Results. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-76-3-112-6-397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.